GlassScriptPhysician profile
Susan M Dimick
NPI 1083663611
$28,121.52
in general payments reported to CMS, 2019-2025
27 companies · $672 in 2025
The $672 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,757 · 2020: $8,559 · 2021: $5,291 · 2022: $1,109 · 2023: $1,399 · 2024: $2,335 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,269 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,622 · Consulting Fee: $515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,268.51 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,622.34 |
| Consulting Fee | $515.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19,655.03 | 2019-2025 | Repatha, Repatha |
| Medicure Pharma INC. | $1,900.04 | 2020-2024 | Zypitamag |
| Kowa Pharmaceuticals America, INC. | $1,544.01 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $696.60 | 2022-2024 | Leqvio |
| Amarin Pharma, INC. | $565.00 | 2019-2023 | |
| Novo Nordisk INC | $540.42 | 2019-2024 | Wegovy |
| Ionis Pharmaceuticals, INC. | $515.00 | 2025 | Tryngolza |
| Bayer Healthcare Pharmaceuticals INC. | $290.29 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $273.73 | 2019-2021 | |
| Esperion Therapeutics, INC. | $264.41 | 2021-2022 | |
| Glaxosmithkline, LLC. | $242.32 | 2023 | Arexvy, Shingrix |
| Abbvie INC. | $203.03 | 2019-2020 | |
| Regeneron Pharmaceuticals, INC. | $197.62 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $191.22 | 2022-2024 | Evkeeza |
| Lilly USA, LLC | $154.86 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Althera Pharmaceuticals LLC | $149.24 | 2021-2022 | |
| Corcept Therapeutics | $143.07 | 2019 | |
| Sanofi-Aventis U.S. LLC | $124.99 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $114.59 | 2023 | Imcivree |
| Teva Pharmaceuticals USA, INC. | $102.31 | 2019 | |
| Merck Sharp & Dohme LLC | $61.58 | 2022 | |
| Janssen Pharmaceuticals, INC | $58.57 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $51.21 | 2021 | |
| Abbott Laboratories | $45.10 | 2023 | Freestyle Libre 3 |
| Therapeuticsmd, INC. | $18.74 | 2020 | |
| Shire North American Group INC | $18.54 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Dimick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.